# Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc. is a company headquartered in Cambridge, MA, United States.

## Company overview

- **Legal name:** Cerevel Therapeutics Holdings, Inc.
- **Former names in filing history:** ARYA Sciences Acquisition Corp II (2020-03-10 to 2020-10-26)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Cambridge, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001805387

## About

Cerevel Therapeutics Holdings, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001805387, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2024-02-27, it reported annual revenue of USD 0; net income of USD -432,842,000; total assets of USD 1,243,298,000 for the fiscal period ended 2023-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2023 (period ended 2023-12-31)

- **Revenue:** $0 (USD 0)
- **Net income:** -$432.8M (USD -432,842,000)
- **Total assets:** $1.2B (USD 1,243,298,000)
- **Cash and equivalents:** $416.5M (USD 416,465,000)
- **Operating cash flow:** -$342.3M (USD -342,301,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $0 (USD 0)
- **Net income:** -$351.5M (USD -351,511,000)
- **Total assets:** $1.0B (USD 1,017,822,000)
- **Cash and equivalents:** $136.5M (USD 136,521,000)
- **Operating cash flow:** -$293.2M (USD -293,187,000)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $0 (USD 0)
- **Net income:** -$225.3M (USD -225,334,000)
- **Total assets:** $688.9M (USD 688,919,000)
- **Cash and equivalents:** $193.0M (USD 193,018,000)
- **Operating cash flow:** -$178.5M (USD -178,546,000)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $0 (USD 0)
- **Net income:** -$152.1M (USD -152,142,000)
- **Total assets:** $445.3M (USD 445,273,000)
- **Cash and equivalents:** $383.6M (USD 383,623,000)
- **Operating cash flow:** -$117.8M (USD -117,802,000)

## Recent SEC filings

- Form 8-K — filed 2024-08-01 — period 2024-08-01 — 8-K
- Form 10-Q — filed 2024-05-08 — period 2024-03-31 — 10-Q
- Form 10-K/A — filed 2024-04-26 — period 2023-12-31 — 10-K/A
- Form 10-K — filed 2024-02-27 — period 2023-12-31 — 10-K
- Form 8-K — filed 2024-02-16 — period 2024-02-16 — 8-K
- Form 8-K — filed 2023-12-07 — period 2023-12-06 — 8-K
- Form 10-Q — filed 2023-11-01 — period 2023-09-30 — 10-Q
- Form 8-K — filed 2023-11-01 — period 2023-11-01 — 8-K
- Form 8-K — filed 2023-10-12 — period 2023-10-11 — 8-K
- Form 8-K — filed 2023-10-11 — period 2023-10-11 — 8-K
- Form 10-Q — filed 2023-08-02 — period 2023-06-30 — 10-Q
- Form 8-K — filed 2023-08-02 — period 2023-08-02 — 8-K

---

Updated: 2026-10-23T19:32:55Z

Canonical page: https://altss.com/profile/cerevel-therapeutics-holdings-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology